Mark Noviski

Mark Noviski

Auto-generated profile, based on publicly available information

Mark Noviski

Nurix Therapeutics, Brisbane, California

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2024 in Science
Verified
Journal Article
Closed access
SMSkye Montoya
Skye Montoya
JBJessie Bourcier
Jessie Bourcier
MNMark Noviski
Mark Noviski
HLHao Lu
Hao Lu
MTMeghan Caitlin Thompson
Meghan Caitlin Thompson
JTJustin Taylor
Justin Taylor
Increasing use of covalent and noncovalent inhibitors of Bruton’s tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies. Here we identify inhibitor resistance mutations in BTK with distinct enzymatic activities, including some that impair BTK enzymatic activity while imparting novel protein-protein interactions that sustain B cell receptor (BCR) signaling. Furthermore, we describe a clinical-stage BTK and IKZF1/3 degrader, NX-2127, that can bind and proteasomally degrade each mutant BTK proteoform, resulting in potent blockade of BCR signaling. Treatment of chronic lymphocytic leukemia with NX-2127 achieves >80% degradation of BTK in patients and demonstrates proof-of-concept therapeutic benefit. These data reveal an oncogenic scaffold function of mutant BTK that confers resistance across clinically approved BTK inhibitors but is overcome by BTK degradation in patients.

9 March 2018 in eLife
Verified
Journal Article
Open access
MNMark Noviski
Mark Noviski
JMJames L Mueller
James L Mueller
ASAnne Satterthwaite
Anne Satterthwaite
LGLee Ann Garrett-Sinha
Lee Ann Garrett-Sinha
FBFrank Brombacher
Frank Brombacher
JZJulie Zikherman
Julie Zikherman
Naive B cells co-express two BCR isotypes, IgM and IgD, with identical antigen-binding domains but distinct constant regions. IgM but not IgD is downregulated on autoreactive B cells. Because these isotypes are presumed to be redundant, it is unknown how this could impose tolerance. We introduced the Nur77-eGFP reporter of BCR signaling into mice that express each BCR isotype alone. Despite signaling strongly in vitro, IgD is less sensitive than IgM to endogenous antigen in vivo and developmental fate decisions are skewed accordingly. IgD-only Lyn−/− B cells cannot generate autoantibodies and short-lived plasma cells (SLPCs) in vivo, a fate thought to be driven by intense BCR signaling induced by endogenous antigens. Similarly, IgD-only B cells generate normal germinal center, but impaired IgG1+ SLPC responses to T-dependent immunization. We propose a role for IgD in maintaining the quiescence of autoreactive B cells and restricting their differentiation into autoantibody secreting cells.

31 August 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
CTCorey Tan
Corey Tan
RHRyosuke Hiwa
Ryosuke Hiwa
JMJames L. Mueller
James L. Mueller
VVVivasvan Vykunta
Vivasvan Vykunta
KHKenta Hibiya
Kenta Hibiya
JZJulie Zikherman
Julie Zikherman

20 October 2019 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
CTCorey Tan
Corey Tan
MNMark Noviski
Mark Noviski
JHJohn Huizar
John Huizar
JZJulie Zikherman
Julie Zikherman

30 March 2023 in Blood
Verified
Journal Article
Open access
PDF file
DZDeyi Zhang
Deyi Zhang
HHHailey M. Harris
Hailey M. Harris
JCJonathan Chen
Jonathan Chen
JJJennifer Judy
Jennifer Judy
GJGabriella James
Gabriella James
AWAdrian Wiestner
Adrian Wiestner
Bruton tyrosine kinase (BTK) is essential for B-cell receptor (BCR) signaling, a driver of chronic lymphocytic leukemia (CLL). Covalent inhibitors bind C481 in the active site of BTK and have become a preferred CLL therapy. Disease progression on covalent BTK inhibitors is commonly associated with C481 mutations. Here, we investigated a targeted protein degrader, NRX-0492, that links a noncovalent BTK-binding domain to cereblon, an adaptor protein of the E3 ubiquitin ligase complex. NRX-0492 selectively catalyzes ubiquitylation and proteasomal degradation of BTK. In primary CLL cells, NRX-0492 induced rapid and sustained degradation of both wild-type and C481 mutant BTK at half maximal degradation concentration (DC50) of ≤0.2 nM and DC90 of ≤0.5 nM, respectively. Sustained degrader activity was maintained for at least 24 hours after washout and was equally observed in high-risk (deletion 17p) and standard-risk (deletion 13q only) CLL subtypes. In in vitro testing against treatment-naïve CLL samples, NRX-0492 was as effective as ibrutinib at inhibiting BCR-mediated signaling, transcriptional programs, and chemokine secretion. In patient-derived xenografts, orally administered NRX-0492 induced BTK degradation and inhibited activation and proliferation of CLL cells in blood and spleen and remained efficacious against primary C481S mutant CLL cells collected from a patient progressing on ibrutinib. Oral bioavailability, >90% degradation of BTK at subnanomolar concentrations, and sustained pharmacodynamic effects after drug clearance make this class of targeted protein degraders uniquely suitable for clinical translation, in particular as a strategy to overcome BTK inhibitor resistance. Clinical studies testing this approach have been initiated (NCT04830137, NCT05131022).

1 November 2017 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
JHJohn Huizar
John Huizar
CTCorey Tan
Corey Tan
MNMark Noviski
Mark Noviski
JMJames L. Mueller
James L. Mueller
JZJulie Zikherman
Julie Zikherman
B-1a cells are a unique population of innate-like B cells with a highly restricted and self-reactive BCR repertoire. Preimmune “natural” IgM produced by B-1a–derived plasma cells is essential for homeostatic clearance of cellular debris and forms a primary layer of protection against infection. In this study, we take advantage of a fluorescent reporter of BCR signaling to show that expression of the orphan nuclear hormone receptor Nur77 is upregulated under steady-state conditions in self-reactive B-1a cells in response to chronic Ag stimulation. Nur77-deficient mice exhibit elevated natural serum IgM (but not IgG) and marked expansion of IgM plasma cells of B-1a origin. Moreover, we show that Nur77 restrains the turnover of B-1a cells and the accumulation of immature IgM plasma cells. Thus, we identify a new critical negative-regulatory pathway that serves to maintain B-1a cells in a quiescent state in the face of chronic endogenous Ag stimulation.